Mafauzy Mohamed

Mafauzy Mohamed

Auto-generated profile, based on publicly available information

Mafauzy Mohamed


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2023 in Diabetes Therapy
Verified
Journal Article
Open access
PDF file
MMMafauzy Mohamed
Mafauzy Mohamed
RZRoberto Luis Zagury
Roberto Luis Zagury
KBKalpana Bhaskaran
Kalpana Bhaskaran
JNJoel Neutel
Joel Neutel
BYBarakatun Nisak Mohd Yusof
Barakatun Nisak Mohd Yusof
OJOdd Erik Johansen
Odd Erik Johansen
Introduction Reducing postprandial (PP) hyperglycemia and PP glucose excursions is important for overall glycemic management. Although most therapeutic lifestyle interventions that reduce caloric intake would affect this, there is no particular nutritional intervention favored. Methods We evaluated the effects of a novel natural food adjuvant combining mulberry leaf extract (MLE) with other bioactive ingredients, in people with type 2 diabetes (T2D) originating from Asia, on improving PP glucometabolic response in a randomized controlled exploratory crossover, two-center study (USA, Singapore). A 2-g blend of 250 mg MLE [containing 12.5 mg of 1-deoxynojirimycin (DNJ)], fiber (1.75 g), vitamin D3 (0.75 μg), and chromium (75 μg), compared with a similar blend without the MLE, was sprinkled over a 350-kcal breakfast meal (55.4 g carbs) and PP blood glucose (primary exploratory endpoint), insulin, and incretin hormones (GLP-1, GIP) were evaluated in blood samples over 3 h. Changes in incremental areas under the concentration curve (iAUC) and maximum concentrations (Cmax) were compared. Results Thirty individuals (12 women, mean age 59 years, HbA1c 7.1%, BMI 26.5 kg/m2) were enrolled and the MLE-based blend relative to the blend without MLE significantly reduced glucose iAUC at 1 h (− 20%, p < 0.0001), 2 h (− 17%, p = 0.0001), and 3 h (− 15%, p = 0.0032) and Cmax [mean (95% CI) difference − 0.8 (− 1.2, − 0.3) mmol/L, p = 0.0006]. A statistically significant reduction in 1 h insulin iAUC (− 24%, p = 0.0236) was observed, but this reduction was no longer present at either 2 h or 3 h. No difference in GLP-1 was seen, but GIP response (iAUC and Cmax) was less with the MLE-based blend. Conclusions The observation of a significant glucose reduction paralleled with a significant lower insulin response supports a reduced gastrointestinal glucose absorption. These results support the use of a 2-g natural blend of MLE, fiber, vitamin D, and chromium in T2D as a convenient dietary adjuvant to improve PP glucometabolic response. ClinicalTrials.gov identifier NCT04877366.


11 December 2020 in Diagnostics
Verified
Journal Article
Open access
PDF file
MAMasliza Hanuni Mat Ali
Masliza Hanuni Mat Ali
TITuan Salwani Tuan Ismail
Tuan Salwani Tuan Ismail
WAWan Norlina Wan Azman
Wan Norlina Wan Azman
NYNajib Majdi Yaacob
Najib Majdi Yaacob
NYNorhayati Yahaya
Norhayati Yahaya
MMMafauzy Mohamed
Mafauzy Mohamed
Thyroid hormones have a catabolic effect on bone homeostasis. Hence, this study aimed to evaluate serum vitamin D, calcium, and phosphate and bone marker levels and bone mineral density (BMD) among patients with different thyroid diseases. This cross-sectional study included patients with underlying thyroid diseases (n = 64, hyperthyroid; n = 53 euthyroid; n = 18, hypothyroid) and healthy controls (n = 64). BMD was assessed using z-score and left hip and lumbar bone density (g/cm2). The results showed that the mean serum vitamin D Levels of all groups was low (<50 nmol/L). Thyroid patients had higher serum vitamin D levels than healthy controls. All groups had normal serum calcium and phosphate levels. The carboxy terminal collagen crosslink and procollagen type I N-terminal propeptide levels were high in hyperthyroid patients and low in hypothyroid patients. The z-score for hip and spine did not significantly differ between thyroid patients and control groups. The hip bone density was remarkably low in the hyperthyroid group. In conclusion, this study showed no correlation between serum 25(OH)D levels and thyroid diseases. The bone markers showed a difference between thyroid groups with no significant difference in BMD.

28 February 2025 in Malaysian Journal of Medical Sciences
Verified
Journal Article
Open access
TKThai Hau Koo
Thai Hau Koo
XLXue Bin Leong
Xue Bin Leong
JNJet Kwan Ng
Jet Kwan Ng
NTNicholas Kay Beng Tan
Nicholas Kay Beng Tan
KEKuala Lumpur InnoDev Digital Enterprise
Kuala Lumpur InnoDev Digital Enterprise
MMMafauzy Mohamed
Mafauzy Mohamed
One in eight people globally, prevalent mainly in some ethnic groups and those from low socioeconomic backgrounds, is a critical global health challenge of obesity. The telehealth system would be valuable in arresting obesity, with better access to care and a supporting digital community that encourages regular practice of physical activities, healthy diets, and health monitoring, all within reach and at affordable prices. Digital health interventions such as telehealth, mHealth applications, and wearable devices are new modalities for the treatment of obesity that increase monitoring of energy expenditure, physical activity level, and caloric intake. These technologies enhance the possibilities of therapy against barriers, such as maintaining motivation and improving the diet. This review summarises current evidence regarding digital health interventions for obesity management by considering and evaluating various global digital strategies to reduce obesity. The literature emphasises the effectiveness of eHealth interventions toward weight loss and maintenance. Furthermore, artificial intelligence (AI) and Information and Communications Technology (ICT) can predict and prevent paediatric obesity. By contrast, virtual reality (VR) applications can determine real-world behaviour in clinical practice. These digital interventions could increase the reach and efficacy of traditional weight management programmes by becoming more embedded in clinical practice. However, because of their broad implementation across different clinical settings, concerns regarding the security and privacy of these technologies must be addressed.

18 May 2023 in Journal of the ASEAN Federation of Endocrine Societies
Verified
Journal Article
Open access
PDF file
MMMafauzy Mohamed
Mafauzy Mohamed
SLSiang Chin Lim
Siang Chin Lim
MMMalik Mumtaz
Malik Mumtaz
SUShweta Uppal
Shweta Uppal
DMDeepak Mukherjee
Deepak Mukherjee
SCSiew Pheng Chan
Siew Pheng Chan
Objective. Insulin degludec (IDeg)/insulin aspart (IAsp; IDegAsp) is a co-formulation of 70% IDeg and 30% IAsp. According to several randomized controlled trials, IDegAsp is effective and safe for patients with type 2 diabetes mellitus (T2DM). A subgroup analysis of the ARISE study was conducted to explore the safety and efficacy of IDegAsp in Malaysian patients with T2DM in real-world settings. Methodology. ARISE, an open-label, multicenter, non-interventional, prospective study was conducted between August 2019 and December 2020. Adult, Malaysian patients with T2DM, enrolled from 14 sites, received IDegAsp as per the local label for 26 weeks. The primary endpoint was change in glycated hemoglobin (HbA1c) levels from baseline to end of study (EOS). Results. Of 182 patients included in the full analysis set, 159 (87.4%) completed the study. From baseline to EOS, HbA1c (estimated difference [ED]: –1.3% [95% CI: –1.61 to –0.90]) and fasting plasma glucose levels (ED: –1.8 mmol/L [95% CI: –2.49 to –1.13]) were significantly reduced (p<0.0001). The patient-reported hypoglycemic episodes (overall and nocturnal) reduced during treatment. Overall, 37 adverse events were observed in 23 (12.6%) patients. Conclusion. Switching or initiating IDegAsp treatment resulted in significant improvements in glycemic control and reduction in hypoglycemic episodes.

21 July 2023 in Journal of Diabetes Science and Technology
Verified
Journal Article
Open access
MMMafauzy Mohamed
Mafauzy Mohamed
NTNikhil Tandon
Nikhil Tandon
YKYoungsoon Kim
Youngsoon Kim
IKIrene Kopp
Irene Kopp
NTNagaaki Tanaka
Nagaaki Tanaka
SBShailendra Bajpai
Shailendra Bajpai
Globally, health care workers (HCWs) are at a high risk of occupational exposure to needlestick injuries (NSIs). Needlestick injuries not only are associated with an increased risk of infections caused by bloodborne pathogens but are also a primary source of emotional distress and job burnout for HCWs and patients. Insulin injection–related NSIs are common among HCWs working in hospitals in the Asia-Pacific (APAC) region and impose a significant burden. Insulin pen needles have a high risk of transmitting infections (at both the patient-end and cartridge end of the sharp) after use. Recapping a needle after administering an insulin injection poses a major risk to HCWs. Currently, several safety-engineered needle devices (SENDs) are available with active or passive safety mechanisms. Passive insulin safety pen needles with dual-ended protection and automatic recapping capabilities have resulted in a significant drop in accidental punctures to HCWs while administering insulin to patients with diabetes. In this article, we have reviewed the burden and common causes of NSIs with insulin injections among HCWs in the APAC region. We have discussed current approaches to address the issues associated with NSIs and the benefits of introducing SENDs in health care settings, including long-term care facilities, nursing homes, and home care settings where patients may require assisted insulin injections. This review also summarizes key strategies/recommendations to prevent NSIs in HCWs and patients with diabetes in the APAC region.